6 results on '"V., Gentile"'
Search Results
2. Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates.
- Author
-
Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, Ragonesi G, Gentile V, and De Berardinis E
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Dihydrotestosterone metabolism, Dutasteride, Humans, Male, Middle Aged, Postoperative Complications prevention & control, Prostate surgery, Prostate-Specific Antigen metabolism, Testosterone metabolism, Treatment Outcome, 5-alpha Reductase Inhibitors administration & dosage, Azasteroids administration & dosage, Blood Loss, Surgical prevention & control, Prostate pathology, Transurethral Resection of Prostate methods
- Abstract
Objective: To investigate if short-term treatment with dutasteride (8 weeks) before bipolar transurethral resection of the prostate (B-TURP) can reduce intraoperative bleeding, as dutasteride a dual 5α-reductase inhibitor (5-ARI) blocks the conversion of testosterone into its active form dihydrotestosterone (DHT), and reduces prostate volume and prostate-specific antigen (PSA) levels, while increasing urinary flow rate., Patients and Methods: In all, 259 patients were enrolled and randomised to two groups: Group A, receiving placebo and Group B, receiving dutasteride (0.5 mg daily for 8 weeks). Blood samples were taken before and after B-TURP for serum chemistry evaluation. In particular we evaluated blood parameters associated with blood loss [haemoglobin (Hb) and haematocrit (Ht)] and prostate vascularity [vascular endothelial growth factor (VEGF) immunoreactivity and microvessel density (MVD) using cluster of differentiation 34 (CD34) immunoreactivity]., Results: Total testosterone, DHT, PSA level and prostate volume were evaluated and with the exception of DHT and PSA level there was no statistically significant differences between the groups. When comparing changes in Hb and Ht between Group A and Group B before and after B-TURP, there was a statistically significant difference only in patients with large prostates of ≥50 mL (ΔHb 3.86 vs 2.05 g/dL and ΔHt 4.98 vs 2.64%, in Groups A and B, respectively). There was no significant difference in MVD and VEGF index in prostates of <50 mL, conversely in large prostates the difference become statistically significant., Conclusions: Dutasteride was able to reduce operative and perioperative bleeding only in patients with large prostates (≥50 mL) that underwent B-TURP. Our findings are confirmed by Hb and Ht values reported before and after the B-TURP and reductions in the molecular markers for VEGF and CD34 in the dutasteride-treated specimens., (© 2014 The Authors BJU International © 2014 BJU International Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
- Author
-
Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, and Salciccia S
- Subjects
- Aged, Biopsy methods, Humans, Male, Middle Aged, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms urine, ROC Curve, Antigens, Neoplasm urine, Biomarkers, Tumor urine, Diffusion Magnetic Resonance Imaging methods, Prostate pathology, Prostatic Neoplasms pathology
- Abstract
Unlabelled: Study Type--Clinical (prospective trial) Level of Evidence 2b. What's known on the subject? and What does the study add? In clinical practice, we know that it is necessary to identify new biomarkers that can better detect prostate cancer (PC), at the same time as reducing the number of unnecessary biopsies. Recently, studies have suggested that the most relevant clinical scenario in which the prostate cancer antigen 3 (PCA3) score could be used comprises patients with a previous negative prostate biopsy and persistently elevated PSA levels. At the same time, although multiparametric MRI is not currently used as a first approach for diagnosing PC, it can be useful for directing targeted biopsies, especially in those patients with elevated PSA levels and a previous negative TRUS-guided biopsy. Considering all of these aspects, the present study aimed to evaluate the role of multiparametric MRI as an additional diagnostic tool for improving the accuracy of the urinary PCA3 test in patients with increased PSA levels and a previous negative prostate biopsy. Our hypothesis is that the potential value of the PCA3 test as a biomarker for PC diagnosis could be improved by the use of multiparametric MRI in directing prostate biopsy. In the present study, we show that, in cases with a previous negative biopsy and persistently elevated PSA levels submitted to multiparametric MRI to direct biopsies, the sensitivity of the PCA3 test significantly improved (79% vs 68%). However, further larger randomized studies on this combination using a new biomarker and a new imaging modality for PC diagnosis are expected., Objective: • To evaluate the role of multiparametric magnetic resonance imaging (MRI) as an additional diagnostic tool for improving the accuracy of the urinary prostate cancer antigen 3 (PCA3) test in patients with an increase in prostate-specific antigen (PSA) levels and a previous negative prostate biopsy., Patients and Methods: • The present study comprised a prospective randomized study on patients with a previous negative transrectal ultrasonography (TRUS)-guided prostate biopsy and elevated PSA levels. • In total, 180 cases were analyzed, and all were submitted to PCA3 assay. • Patients in group A were submitted to a second random TRUS-guided prostate biopsy, whereas patients in group B were submitted to a multiparametric MRI examination and then to a second TRUS-guided prostate biopsy., Results: • At the second biopsy, a histological diagnosis of prostate cancer was found in 26 of 84 cases (30.9%) in group A and in 29 of 84 cases (34.5%) in group B. • In group A, the sensitivity and specificity of the PCA3 score were 68.0% and 74.5% respectively (positive predictive value of 53.1%, negative predictive value of 84.6% and accuracy of 72.6%). • In group B, the sensitivity and specificity of the PCA3 score were 79.3% and 72.7%, respectively (positive predictive value of 60.5%, negative predictive value of 86.9% and accuracy of 75.0%). • For the PCA3 score, the area under the receiver-operator characteristic curve was 0.825 (95% confidence interval, 0.726-0.899) in group A and 0.857 (95% confidence interval, 0.763-0.924) in group B (P < 0.001)., Conclusion: • In patients with a previous negative biopsy and persistently elevated PSA levels, the use of multiparametric MRI for indicating sites suitable for rebiopsy can significantly improve the sensitivity of the PCA3 test in the diagnosis of prostate cancer., (© 2012 BJU INTERNATIONAL.)
- Published
- 2012
- Full Text
- View/download PDF
4. Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature.
- Author
-
Iacovelli R, Altavilla A, Ciardi A, Urbano F, Manai C, Gentile V, and Cortesi E
- Subjects
- Adult, Disease-Free Survival, Female, Humans, Kidney Neoplasms chemistry, Kidney Neoplasms genetics, Kidney Neoplasms mortality, Male, Middle Aged, Prognosis, Sarcoma, Synovial chemistry, Sarcoma, Synovial genetics, Sarcoma, Synovial mortality, Survival Rate, Kidney Neoplasms pathology, Sarcoma, Synovial pathology
- Abstract
Objective: To describe, for the first time, the clinical characteristics of primary renal synovial sarcoma (SS) and to examine the association of histological features with the expression of immunohistochemical markers., Patients and Methods: We collated published data on all cases of primary renal SS, from its first description in 2000 to September 2011. Data on clinical and pathological characteristics were extracted and used to create a database. Disease-free survival (DFS) and overall survival (OS) rates were estimated using the Kaplan-Meier method with Rothman's 95% confidence intervals (CIs) and compared across the groups using the log-rank test. The associations between tumour extension and histological features were evaluated using the non-parametric Spearman rank test. A chi-squared test was used to assess the differences between groups., Results: In the overall cohort, the median OS was 48 months (95% CI, 14.1-81.9). Cox analysis showed that the risk of death at diagnosis was greatly increased in patients with metastatic disease compared with those with non-metastatic disease (hazard ratio [HR]: 343.9, 95% CI, 2.8-42,000; P= 0.017). The median DFS was 33.0 months (95% CI, 16.8-49.2), and patients who develop metastatic disease have a very poor prognosis with a median survival of 6 months (95% CI, 5.1-6.9). Microscopic features were monophasic, biphasic and poorly differentiated synovial sarcoma in 76, 16 and 8% of patients, respectively. Significant differences in expression of immunohistochemical markers or genetic mutation were found between different subtypes., Conclusions: Despite its retrospective nature, this study shows that renal SS comprises different histological subtypes, which are characterized by specific immunohistochemical stains and by specific translocations. When diagnosed at metastatic stage, the prognosis was very poor compared with that for non-metastatic disease, even though one out of three patients with non-metastatic disease had disease relapse. Cooperative efforts and publication of cases with adequate follow-up are necessary to better define prognosis and therapeutic strategies for this rare disease., (© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.)
- Published
- 2012
- Full Text
- View/download PDF
5. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
- Author
-
Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, and Beardsworth A
- Subjects
- 3',5'-Cyclic-GMP Phosphodiesterases, Adult, Aged, Analysis of Variance, Carbolines adverse effects, Coitus, Cyclic Nucleotide Phosphodiesterases, Type 5, Double-Blind Method, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors adverse effects, Tadalafil, Treatment Outcome, Carbolines therapeutic use, Erectile Dysfunction drug therapy, Phosphodiesterase Inhibitors therapeutic use, Phosphoric Diester Hydrolases
- Abstract
Objective: To evaluate, in a randomized, double-blind, placebo-controlled, multicentre trial, the safety and efficacy of on-demand tadalafil (an oral phosphodiesterase type-5 inhibitor approved in many countries for treating erectile dysfunction, ED) in a Western European population of men with mild-to-severe ED., Patients and Methods: Patients were randomized according to baseline severity of ED in a ratio of 3 : 1 to receive either tadalafil 20 mg or placebo for 12 weeks. Primary efficacy endpoints were mean changes from baseline to endpoint (12 weeks) in the erectile function (EF) domain of the International Index of Erectile Function (IIEF) and percentages of 'Yes' responses to Sexual Encounter Profile (SEP) diary Question 2 ('Were you able to insert your penis into your partner's vagina?') and Question 3 ('Did your erection last long enough for you to have successful intercourse?'). Secondary endpoints included mean changes from baseline to endpoint in IIEF Intercourse Satisfaction and Overall Satisfaction domains, selected questions of the IIEF, and the percentage of 'Yes' responses to Global Assessment Questions (GAQ) at the last visit. Other analyses included the percentage of patients in each treatment group at endpoint with IIEF EF domain scores in the normal range (>26), the frequency of intercourse attempts and mean per-patient intercourse success rate at various times after dosing., Results: The mean age of the patients was 53 years and 80% had a history of ED of > or = 1 year. The mean baseline EF domain score was 13.5, with 40.5% of patients in the severe category. Tadalafil improved mean EF domain scores by 11.1, vs 0.4 for placebo (P < 0.001). In addition, 73.9% of sexual intercourse attempts were successful (SEP-Q3) in tadalafil-treated patients, compared with 29.9% in placebo-treated patients during the period after baseline (P < 0.001). Tadalafil significantly improved the mean IIEF intercourse satisfaction (5.1, tadalafil; 1.1, placebo) and overall satisfaction domain scores (3.9, tadalafil; 0.5, placebo), P < 0.001. GAQs used to assess the overall effect of the treatment indicated that tadalafil was superior to placebo (P < 0.001) in improving erections (82.1%, tadalafil; 23.1%, placebo) and sexual activity (78.6% and 17.3%). The most common treatment-emergent adverse events more frequent (>2%) with tadalafil than placebo were headache, dyspepsia, flushing, back pain, pain in limb and myalgia. These adverse events were mostly mild to moderate., Conclusions: Tadalafil improved erectile function and was well tolerated when taken by men from Western Europe with mild-to-severe ED.
- Published
- 2004
- Full Text
- View/download PDF
6. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?
- Author
-
Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, and Di Silverio F
- Subjects
- Antineoplastic Agents, Hormonal therapeutic use, Biomarkers, Tumor blood, Cell Differentiation, Cell Transformation, Neoplastic, Humans, Male, Neuroendocrine Tumors drug therapy, Prostate pathology, Prostatic Hyperplasia pathology, Prostatic Intraepithelial Neoplasia pathology, Prostatic Neoplasms drug therapy, Neuroendocrine Tumors pathology, Neurosecretory Systems cytology, Prostate cytology, Prostatic Neoplasms pathology
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.